Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
10.1097/CM9.0000000000001454
- Author:
Taejun YOON
1
;
Sung Soo AHN
2
;
Jung Yoon PYO
2
;
Jason Jungsik SONG
2
;
Yong-Beom PARK
2
;
Sang-Won LEE
2
Author Information
1. Department of Medical Science, BK21 Plus Project, Yonsei University, College of Medicine, Seoul, Republic of Korea.
2. Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Publication Type:Journal Article
- MeSH:
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;
Female;
Follistatin;
Follistatin-Related Proteins;
Functional Status;
Humans;
Male;
Middle Aged;
Prospective Studies;
Severity of Illness Index
- From:
Chinese Medical Journal
2021;134(10):1168-1174
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Follistatin-like 1 (FSTL1) plays both pro-inflammatory and anti-inflammatory roles in the inflammatory processes. We investigated whether serum FSTL1 could predict the current anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)-specific indices.
METHODS:We randomly selected 74 patients with AAV from a prospective and observational cohort of Korean patients with AAV. Clinical and laboratory data and AAV-specific indices were recorded. FSTL1 concentration was determined using the stored sera. The lowest tertile of the short-form 36-item health survey (SF-36) was defined as the current low SF-36. The cutoffs of serum FSTL1 for the current low SF-36 physical component summary (PCS) and SF-36 mental component summary (MCS) were extrapolated by the receiver operator characteristic curve.
RESULTS:The median age was 62.5 years (55.4% were women). Serum FSTL1 was significantly correlated with SF-36 PCS (r = - 0.374), SF-36 MCS (r = -0.377), and C-reactive protein (CRP) (r = 0.307), but not with Birmingham vasculitis activity score (BVAS). In the multivariable linear regression analyses, BVAS, CRP, and serum FSTL1 were independently associated with the current SF-36 PCS (β = -0.255, β = -0.430, and β = -0.266, respectively) and the current SF-36 MCS (β = -0.234, β =-0.229, and β = -0.296, respectively). Patients with serum FSTL1 ≥779.8 pg/mL and those with serum FSTL1 ≥841.6 pg/mL exhibited a significantly higher risk of having the current low SF-36 PCS and SF-36 MCS than those without (relative risk 7.583 and 6.200, respectively).
CONCLUSION:Serum FSTL1 could predict the current functional status in AAV patients.
